Skip to content

Comparative Study Between Conventional Radiofrequency Ablation vs Chemical Neurolysis of Ganglion Impar for Treatment of Chronic Non Cancer Related Coccydynia

Comparative Study Between Conventional Radiofrequency Ablation vs Chemical Neurolysis of Ganglion Impar for Treatment of Chronic Non Cancer Related Coccydynia

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07247565
Enrollment
74
Registered
2025-11-25
Start date
2025-03-01
Completion date
2025-12-31
Last updated
2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Management

Keywords

coccydinea, pain, radiofrequency, alcohol neurolysis

Brief summary

Aim: compare effectiveness (satisfaction) and duration of pain relief between patients who perform the conventional thermal radiofrequency on the ganglion impar vs patients who perform the chemical neurolysis with alcohol in patients with non cancer coccydynia patients with non cancer coccydynia not responding to medical treatment will be divided into 2 groups before intervention , control group will receive conventional radiofrequency ablation of ganglion impar , while the study group will receive alcohol neurolysis

Interventions

The entry site was detected under fluoroscopy then local anesthesia was given using lidocaine 2% followed by the insertion of a radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the junction between the coccygeal bones and pass through it anteriorly in the lateral view. Finally confirming the proper site with a contrast dye in lateral and A-P views. 10 ml of lidocaine 1 % was injected to tolerate the ablation then in the 1st group placing of the radiofrequency cable followed by ablation will be done at 80 degrees for 90 seconds.

The entry site was detected under fluoroscopy then local anesthesia was given using lidocaine 2% followed by the insertion 22 G spinal needle targeting the junction between the coccygeal bones and pass through it anteriorly in the lateral view. Finally confirming the proper site with a contrast dye in lateral and A-P views. 10 ml of lidocaine 1 % was injected to tolerate the ablation then injection of 5 ml 70% alcohol will be performed

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* non cancer coccydynia 1. Both genders 2. Age between 20-70 years. 3. ASA 1,2 & 3 physical status 4. xray coccyx lateral position showing normal joints and bones with no fractures

Exclusion criteria

* Neurological disorders. (previous central and peripheral CNS affection). * coagulopathy INR \> 1.8 or platelets \< 50,000. * Infection at or near the injection site. * Presence of pacemaker or defibrillator. * known allergy to used medications. * patients with previous history of Radiotherapy, chemotherapy or metastasis * pregnant patients. * patients with rheumatological disorders (rheumatoid arthritis, diffuse idiopathic skeletal hyerostosis, psoriatic arthritis) * age \<20 or \>70 * Xray coccyx showing fractures or abnormalities

Design outcomes

Primary

MeasureTime frameDescription
pain relief using Numeric Pain score scale1 monthpatients will be asked to describe their pain on Numeric pain scale ( an 11 numbers scale where 0 describes no pain and 10 describes the worst pain ) and compare it to before the procedure
pain relief of chronic non cancer coccydynia6 months after the procedurepatients will be asked to describe their pain on Numeric pain scale and compare it to before the procedure
patient global impression of change (PGIC)6 monthsone-item questionnaire that asks patients to rate their overall improvement after a treatment.he scale typically includes ratings such as very much improved, much improved, minimally improved, unchanged, or worse.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026